Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Mutant Endometrial Cancer
A Phase Ib trial is underway to evaluate the safety and dosing of a combination therapy for RAS pathway mutant endometrial cancer.
Phase III
M.D. Anderson Cancer Center
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing Phase Ib trial for a combination therapy targeting RAS pathway mutations in endometrial cancer is significant as it may establish new treatment options in a niche market. Success could enhance the competitive positioning of Verastem and its collaborators in the oncology landscape, particularly in targeted therapies.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor for updates on dosing recommendations and safety results as they may influence future development strategies.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.